ATP10A

Chr 15

ATPase phospholipid transporting 10A (putative)

Also known as: ATP10C, ATPVA, ATPVC

This gene encodes a P4-ATPase flippase that transports phosphatidylcholine from the outer to inner leaflet of the plasma membrane, facilitating membrane bending and integrin endocytosis. Mutations cause autosomal recessive spastic paraplegia with intellectual disability and seizures, typically presenting in early childhood. The gene is highly constrained against loss-of-function variants and is maternally expressed, located within the common deletion interval associated with Angelman syndrome.

GeneReviewsOMIMResearchSummary from RefSeq, UniProt
MultiplemechanismLOEUF 0.43
Clinical SummaryATP10A
Population Constraint (gnomAD)
Constrained for loss-of-function variants (OE-LoF 0.28) despite low pLI — interpret in context.
📋
ClinVar Variants
160 unique Pathogenic / Likely Pathogenic· 245 VUS of 486 total submissions
📖
GeneReview available — ATP10A
Authoritative clinical overview · Recommended first read
Open GeneReview ↗

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Moderate LoF intolerance
LoF Constraint
0.43LOEUF
pLI 0.002
Z-score 5.12
OE 0.28 (0.190.43)
Moderately constrained

More LoF-intolerant than ~75% of genes

Missense Constraint
0.76Z-score
OE missense 0.93 (0.880.98)
824 obs / 887.7 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios
LoF OE0.28 (0.190.43)
00.351.4
Missense OE0.93 (0.880.98)
00.61.4
Synonymous OE1.00
01.21.6
LoF obs/exp: 17 / 59.7Missense obs/exp: 824 / 887.7Syn Z: 0.00
DN
0.77top 25%
GOF
0.77top 25%
LOF
0.2581th %ile

This gene has evidence for multiple mechanisms of pathogenicity (gain-of-function and dominant-negative). Both the Badonyi & Marsh prediction and the broader genomic evidence point to gain-of-function as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

GOFprediction above median
DNprediction above median

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312.

ClinVar Variant Classifications

486 submitted variants in ClinVar

Classification Summary

Pathogenic157
Likely Pathogenic3
VUS245
Likely Benign39
Benign14
Conflicting1
157
Pathogenic
3
Likely Pathogenic
245
VUS
39
Likely Benign
14
Benign
1
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
0
157
0
157
Likely Pathogenic
0
0
3
0
3
VUS
1
240
4
0
245
Likely Benign
0
19
3
17
39
Benign
0
9
2
3
14
Conflicting
1
Total126816920459

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

ATP10A · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

3D Protein StructureAlphaFold

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →
Clinical Literature
Open Research Assistant →